{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-007720","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2022-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.565772+00:00","generated_at":"2026-06-26T14:06:47.043956+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Mesa files Agena financials post-acquisition; revises segment reporting structure","bullets":["Agena's revenue for nine months ended Sep 30, 2021: $58.4M, up 45% YoY; net income of $12.8M vs loss of $0.38M.","Mesa recast FY2021 segment data into four segments: Sterilization/Disinfection, Clinical Genomics (Agena), Biopharma Development, Calibration Solutions.","Pro forma combined statement for nine months ended Dec 31, 2021 filed; acquisition closed Oct 20, 2021.","Agena's cash and equivalents fell to $3.7M from $16.1M at Dec 31, 2020; debt repaid $22.5M during period."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-007720","json":"https://secwatch.observer/filing/0001437749-22-007720.json","markdown":"https://secwatch.observer/filing/0001437749-22-007720.md","text":"https://secwatch.observer/filing/0001437749-22-007720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774922007720/0001437749-22-007720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774922007720/mlab20220309_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T14:06:47.043956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}